REG - Bank Pekao SA - Shareholders holding at least 5% of votes at OGM

Bank Polska Kasa Opieki SAAnnouncement

26/05/2020 07:04

RNS Number : 8149N
  
Bank Pekao S.A.
  
22 May 2020
  
 

UNOFFICIAL TRANSLATION
 
22.05.2020 - Report 32/2020: Shareholders holding at least 5% of votes at the Ordinary General Meeting of Bank Polska Kasa Opieki Spółka Akcyjna on 22 May 2020
 
Content of the report:
The Bank Polska Kasa Opieki Spółka Akcyjna (the "Bank") informs that at the Ordinary General Meeting of the Bank on 22 May 2020 ("Ordinary General Meeting") were represented shareholders holding 161,323,808 shares, entitling to 161,323,808 votes, representing 61.46% of the share capital of the Bank and of the total number of votes at the Bank.
At least 5% of the votes at this Ordinary General Meeting was held by:
1.   Powszechny Zakład Ubezpieczeń S.A, entitled to 52,494,007 votes from its shares, representing 32.54% of votes at the Ordinary General Meeting and 20.00% of the total number of votes at the Bank;
2.   Polski Fundusz Rozwoju S.A., entitled to 33,596,166 votes from its shares, representing 20.83% of votes at the Ordinary General Meeting and 12.80% of the total number of votes at the Bank;
3.   Nationale Nederlanden Otwarty Fundusz Emerytalny, entitled to 13,607,000 votes from its shares, representing 8.43% of votes at the Ordinary General Meeting  and 5.18% of the total number of votes at the Bank;
4.   Aviva Otwarty Fundusz Emerytalny Aviva Santander, entitled to 13,281,544 votes from its shares, representing  8.23% of votes at the Ordinary General Meeting and 5.06% of the total number of votes at the Bank.
Legal basis:
Article 70  point 3 of the Act on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organised Trading, and Public Companies (uniform text: Journal of Laws of 2019, item 623 with further amendments).


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
MSCUURWRRBUVUAR